Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 26, Issue 2, 2007, Pages 89-103

  Curnow, Alison ^a   Pye, Andrew ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

1,2 diethyl 3 hydroxypyridin 4 one hydrochloride (CP94); 5 aminolaevulinic acid (5 ALA); Desferrioxamine (DFO); Iron chelator; photodynamic therapy (PDT); Porphyrin; protoporphyrin IX (PPIX)

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; DEFEROXAMINE; PORPHYRIN; PORPHYRIN DERIVATIVE;

ANALYTIC METHOD; CELL CULTURE; CHEMICAL ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FIBROBLAST; FLUORESCENCE; HUMAN; HUMAN CELL; IRON CHELATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 34548067679     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v26.i2.40     Document Type: Conference Paper

References (35)

1. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-57.
2. Luna MC, Ferrario A, Wong S, Fisher AM, Gomer CJ. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res. 2000;60:1637-44.
3. Diamond I, Granelli SG, McDonagh AF, Nielsen S, Wilson CB, Jaenicke R. Photodynamic therapy of malignant tumours. Lancet. 1972;2:1175-7.
4. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinical useful photosensitiser for photodynamic therapy. J Photochem Photobiol B: Biol. 1992;14:275-92.
5. Morton CA. The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments? J Dermatolog Treat. 2002;13:S25-9.
6. Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Andersson-Engels S, Berg R, Johansson J, Svanberg S. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical 5-aminolaevulinic acid sensitisation and laser irradiation. Br J Dermatol. 1994;130:743-51.
7. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM. 5-Aminolaevulinic-based photodynamic therapy. Am Cancer Soc. 1997;79:2282-308.
8. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol. 2000;142:338-9.
9. Rhodes LE, De Rie M, Enstrom Y, Groves R, Morken T, Goulden V, Wong GA, Grob JJ, Varma S, Wolf P. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140:17-23.
10. CA Morton. Methyl aminolevulinate (Metvix®) photodynamic therapy - practical pearls. J Dermatol Treatment. 2003;14:S23-6.
11. Orenstein A, Kostenich G, Roitman L, Tsur H, Katanick D, Kopolovic J, Ehrenberg B, Malik Z. Photodynamic therapy of malignant lesions of the skin mediated by topical application of 5-aminolevulinic acid in combination with DMSO and EDTA. Lasers Life Sci. 1996;7:49-57.
12. Ibbotson SH, Jong C, Lesar A, Ferguson JS, Padgett M, O'Dwyer M, Barnetson R, Ferguson J. Characteristics of 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence in human skin in vivo. Photodermatol Photoimmunol Photomed. 2006;22:105-10.
13. Messmann H, Mlkvy P, Buonaccorsi G, Davies CL, MacRobert AJ, Bown SG. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer. 1995;72:589-94.
14. Curnow A, McIlroy BW, Postle-Hacon MJ, MacRobert AJ, Bown SG. Light dose fractionation to enhance photodynamic therapy using 5-aminolaevulinic acid in the normal rat colon. Photochem Photobiol. 1999;69:71-6.
15. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol. 1998;67:140-9.
16. Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM, Antitumor effect of 5-aminolaevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res. 2001;61:5824-32.
17. Orenstein A, Kostenich G, Kopolovic Y, Babushkina T, Malik Z. Enhancement of ALA-PDT damage by IR-induced hyperthermia on a colon carcinoma model. Photochem Photobiol. 1999;69:703-7.
18. Juzeniene A, Juzenas P, Bronshtein I, Vorobey A, Moan J. The influence of temperature on photodynamic cell killing in vitro with 5-aminolevulinic acid. J Photochem Photobio B: Biol. 2006;84:161-6.
19. Lopez RF, Bentley MV, Delgado-Charro MB, Salomon D, van den Bergh H, Lange N, Guy RH. Enhanced delivery of 5-aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol. 2003;77:304-8.
20. Bremner JCM, Adams GE, Pearson JK, Sansom JM, Stratford IJ, Bedwell J, Bown SG, MacRobert AJ, Philips D. Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145. Br J Cancer. 1992;66:1070-6.
21. Bhasin G, Kausar H, Athar M. Protoporphyrin-IX accumulation and cutaneous tumor regression in mice using a ferrochelatase inhibitor. Cancer Lett. 2002;187:9-16.
22. Chang SC, MacRobert AJ, Porter JB, Bown SG. The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. J Photochem Photobiol B: Biol. 1997;-38:114-22.
23. Richardson D, Ponka P, Baker E. The effect of the iron (III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 1994;54:685-9.
24. Hanania J, Malik Z. The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitisation of human K562 leukemic cells. Cancer Lett. 1992;65:127-31.
25. Berg K, Anholt H, Bech O, Moan J. The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells. Br J Cancer. 1996;74:688-97.
26. Ortel B, Tanew A, Honigsmann H. Lethal photosensitisation by endogenous porphyrins of PAM cells - modification by desferrioxamine. J Photochem Photobiol B: Biol. 1993;17:273-8.
27. Brittenham GM. Development of iron-chelating agents for clinical use. Blood. 1992;80:569-74.
28. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol. 1993;85:393-400.
29. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture. Blood. 1991;77:2049-53.
30. Bech O, Phillips D, Moan J, MacRobert AJ. A hydroxypyridinone (CP94) enhances protoporphyrin IX formation in 5-aminolaevulinic acid treated cells. J Photochem Photobiol B: Biol. 1997;41:136-44.
31. Curnow A, McIlroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ, Bown SG. Enhancement of 5-aminolaevulinic acid induced photodynamic therapy using iron chelating agents. Br J Cancer. 1998;78:1278-82.
32. Curnow A, MacRobert AJ, Bown SG. Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolaevulinic acid. Lasers Surg Med. 2006;38:325-31.
33. Juzenas P, Juzeniene A, Moan J. Deferoxamine photosensitizes cancer cells in vitro. Biochem Biophys Res Commun. 2005;332:388-91.
34. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol. 1995;133:282-8.
35. Choudry K, Brooke RC, Farrar W, Rhodes LE. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 2003;149:124-30.